Clinical Catch-up for June 10-14
Lilly’s Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
New Biktarvy spot puts Gilead in top TV-spending ranks, right behind AbbVie and Pfizer
Novo Nordisk’s semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
7 drugs that raised eyebrows in Q3
Lilly’s under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
Viagra no more: The changing face of drug ads on TV
Pharma TV buys so far top last year’s $1B spend; AbbVie, Pfizer lead September
Dive Brief: Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication. Set to the tune … Continue Reading With diabetes competitive as ever, Novo launches Ozempic DTC campaign
While Humira held its ad spending crown yet again in May, Latuda jumped up to knock Lyrica from the No. 2 spot it’s held for the past few months. Sunovion … Continue Reading In May TV spending, Sunovion jumps to 2nd, but AbbVie easily keeps top spot